Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors

RRx-001 is an anticancer agent that subjects cancer cells to reactive oxygen/nitrogen species (ROS/RNS) and acts as an epigenetic modifier. We have used a thiol-bearing MRI contrast agent, Gd-LC7-SH, to investigate the pharmacodynamics of RRx-001 in CHP-100 Ewing's Sarcoma, HT-29 colorectal car...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Raghunand, Natarajan, Scicinski, Jan, Guntle, Gerald P., Jagadish, Bhumasamudram, Mash, Eugene A., Bruckheimer, Elizabeth, Oronsky, Bryan, Korn, Ronald L.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Clinical Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5731976/
https://ncbi.nlm.nih.gov/pubmed/29254266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18455
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars